Skip to Content

Generic Triferic Availability

Triferic is a brand name of ferric pyrophosphate, approved by the FDA in the following formulation(s):

TRIFERIC (ferric pyrophosphate citrate - for solution;intravenous)

  • Manufacturer: ROCKWELL MEDICAL INC
    Approval date: April 25, 2016
    Strength(s): 272MG IRON/PACKET [RLD]

TRIFERIC (ferric pyrophosphate citrate - solution;iv (infusion))

  • Manufacturer: ROCKWELL MEDICAL INC
    Approval date: January 23, 2015
    Strength(s): 27.2MG IRON/5ML (5.44MG IRON/ML) [RLD]
  • Manufacturer: ROCKWELL MEDICAL INC
    Approval date: September 4, 2015
    Strength(s): 272MG IRON/50ML (5.44MG IRON/ML)

Has a generic version of Triferic been approved?

No. There is currently no therapeutically equivalent version of Triferic available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Triferic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method and pharmaceutical composition for replacing iron losses in dialysis patients
    Patent 6,689,275
    Issued: February 10, 2004
    Inventor(s): Ajay; Gupta
    A method of replacing iron losses during dialysis of patients is accomplished by infusion of a noncolloidal ferric compound, soluble in hemodialysis solutions, during dialysis. A pharmaceutical composition is provided consisting essentially of dialysis solution including a soluble noncolloidial ferric compound, preferably ferric pyrophosphate.
    Patent expiration dates:
    • December 31, 2016
      ✓ 
      Patent use: METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
  • Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
    Patent 6,779,468
    Issued: August 24, 2004
    Inventor(s): Ajay; Gupta
    A method of administering iron to dialysis patients is accomplished by infusion of a noncolloidal ferric compound, soluble in hemodialysis or peritoneal dialysis solutions, by the process of dialysis. A pharmaceutical composition is provided consisting essentially of dialysis solution including a soluble noncolloidal ferric compound, preferably ferric pyrophosphate.
    Patent expiration dates:
    • December 31, 2016
      ✓ 
      Patent use: METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
  • Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
    Patent 7,816,404
    Issued: October 19, 2010
    Inventor(s): McCall, Jr.; William S.
    Assignee(s): Rockwell Medical Technologies, Inc.
    A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts.
    Patent expiration dates:
    • April 17, 2029
      ✓ 
      Patent use: METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide